Tumor targeting and SPECT imaging properties of an 111In-labeled galectin-3 binding peptide in prostate carcinoma

Nuclear Medicine and Biology

Volumn 36, Issue 2, 2009, Pages 137-146

  Deutscher, Susan L ^a,b   Figueroa, Said D ^b   Kumar, Senthil R ^a  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Galectin 3; Imaging; Peptide; Prostate cancer

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALANYLASPARAGINYLTHREONYLPROLYLCYSTEINYLGLYCYLPROLYL TYROSYLGLYCYLPROLYLTYROSYLTHREONYLHISTIDYLASPARTYLCYSTEINYLPROLYLVALYLLYSYLARGIN INAMIDE; AMIDE; GALECTIN 3; GALECTIN 3 BINDING PEPTIDE; GLYCYLSERYLGLYCINAMIDE; INDIUM 111; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL ADHESION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PHAGE DISPLAY; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; GALECTIN 3; GLYCOPROTEINS; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MALE; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 59649121789     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.10.015     Document Type: Article

References (42)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 (2007) 43-66
2. Stetler-Stevenson W.G., Aznavoorian S., and Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 9 (1993) 541-573
3. Liotta L.A. Cancer cell invasion and metastasis. Sci Am 266 (1992) 54-63
4. Inohara H., and Raz A. Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 55 (1995) 3267-3271
5. Bussemakers M.J., and Schalken J.A. The role of cell adhesion molecules and proteases in tumor invasion and metastasis. World J Urol 14 (1996) 151-156
6. Barondes S.H., Cooper D.N., Gitt M.A., and Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269 (1994) 20807-20810
7. Sato S., and Hughes R.C.J. Regulation of secretion and surface expression of Mac-2, a galactoside binding protein of macrophages. J Biol Chem 269 (1994) 4424-4430
8. Moutsatsos I.K., Wade M., Schindler M., and Wang J.L. Endogenous lectins from cultured cells: nuclear localization of carbohydrate binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci USA 84 (1987) 6452-6456
9. Perillo N.L., Marcus M.E., and Baum L.G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76 (1998) 402-412
10. Sato S., Burdett I., and Hughes R.C. Secretion of the baby hamster kidney 30-kDA galactose binding lectin from polarized and nonpolarized cells: a pathway independent of the endoplasmic reticulum-Golgi complex. Exp Cell Res 207 (1993) 8-18
11. Wang I., Inohara H., Pienta K.J., and Raz A. Galectin-3 is a nuclear matrix protein which binds RNA. Biochem Biophys Res Commun 217 (1995) 292-303
12. Raz A., and Lotan R. Lectin-like activities associated with human and murine neoplastic cells. Cancer Res 41 (1981) 3642-3647
13. Raz A., Zhu D., Hogan V., Shan N., Raz T., Karkash R., et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 46 (1990) 871-877
14. Inohara H., Akahani S., Koths S., and Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 56 (1996) 4530-4534
15. Glinsky V.V., Glinsky G.V., Rittenhouse-Olson K., Huflejt M.E., Glinskii O.V., Deutscher S.L., and Quinn T.P. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61 (2001) 4851-4857
16. Lehr J.E., and Pienta K.J. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90 (1998) 118-123
17. Glinsky V.V., Glinsky G.V., Glinskii O.V., Huxley V.H., Turk J.R., Mossine V.V., Deutscher S.L., Pienta K.J., and Quinn T.P. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 63 (2003) 3805-3811
18. Nangia-Makker P., Hogan V., Honjo Y., Baccarini S., Tait L., Bresalier R., and Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94 (2002) 1854-1862
19. Glinsky G.V., Price J.E., Glinsky V.V., Mosine V.V., Kiriakova G., and Metcalf J.B. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res 56 (1996) 5319-5324
20. Zuo J., Glinsky V.V., Landon L.A., Mathews L., and Deutscher S.L. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 26 (2005) 309-318
21. 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor-expressing breast carcinomas. Clin Cancer Res 20 (2007) 6070-6079
22. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. J Nucl Med 49 (2008) 796-803
23. Iurisci I., Tinari N., Natoli C., Angelucci D., Cianchetti E., and Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6 (2000) 1389-1393
24. Ahemed H., Banerjee P.P., and Vasta G.R. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 358 (2007) 241-246
25. Pacis R.A., Pilat M.J., Pienta K.J., Wojno K., Raz A., Hogan V., et al. Decreased galectin-3 expression in prostate cancer. Prostate 44 (2000) 118-123
26. Schubiger P.A., Alberto A., and Smith A. Vehicles, chelators, and radionuclides: choosing the building blocks of an effective therapeutic radioimmunoconjugate. Bioconj Chem 7 (1996) 165-179
27. Furtak V., Hatcher F., and Ochieng J. Galectin-3 mediates the endocytosis of beta-1 integrins by breast carcinoma cells. Biochem Biophy Res Commun 289 (2001) 845-850
28. Zhu W.Q., and Ocheing J. Rapid release of intracellular galectin-3 from breast carcinoma cells by fetuin. Cancer Res 61 (2001) 1869-1873
29. Mørgenson C.E., and Sølling K. Studies on renal tubular protein re-absorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 37 (1977) 477-486
30. Silbernagl S. The renal handling of amino acids and oligopeptides. Physiol Rev 68 (1988) 912-986
31. Maack T., Johnson V., Kan S.T., Figueiredo J., and Sigulem D. Renal filtration, transport, and metabolism of low molecular weight proteins: a review. Kidney Int 16 (1979) 251-270
32. 188Re labeled alpha-melanocyte hormone stimulating hormone peptide analogs for melanoma therapy. Int J cancer 101 (2002) 480-487
33. Behr T.M., Starkey R.M., Juweid M.E., Blumenthal R.D., Dunn R.M., Griffiths G.L., et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 55 (1995) 3825-3834
34. Rolleman E.J., Valkema R., de Jong M., Kooij P.P.M., and Krenning E.P. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30 (2003) 9-15
35. Perik P.J., Lub-De Hooge M.N., Gietema J.A., van der Graaf W.T.A., Alexander de Korte M., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24 (2006) 2276-2281
36. 111In-octreotide in mice and rats. J Nucl Med 47 (2006) 528-533
37. Vegt E., Wetzels J.F.M., Russell F.G.M., Masereeuw R., Boerman O.C., van Eerd J.E., et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47 (2006) 432-436
38. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., et al. Radionuclide therapy of HER2-specific affibody molecule. Cancer Res 67 (2007) 2773-2782
39. Sehgal I., Foster T.P., and Francis J. Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis. Cancer Cell Int 6 (2006) 21
40. Foster B.A., Kaplan P.J., and Greenburg N.M. Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev 17 (1999) 317-324
41. Hurwitz A.A., Foster B.A., Allison J.P., Greenberg N.M., and Kwon E.D. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol (2001) [Chapter 20: Unit 20.5]
42. Arap W., Kolonin M.G., Trepel M., Lahdenranta J., Cardó-Vila M., Giordano R.J., et al. Steps toward mapping the human vasculature by phage display. Nat Med 8 (2002) 121-127